NOVELIX PHARMACEUTICALS LIMITE Share Price

NOVELIX PHARMACEUTICALS LIMITE Share Price

BSE: 536565
|
Trading
|
S Cap
₹ 73.97
+₹0.98 (1.34%)
1D
Last updated 13 Aug, 2026, 15:05 IST

NOVELIX PHARMACEUTICALS LIMITE Share Price Today

As of 14 Aug 2026, NOVELIX PHARMACEUTICALS LIMITE share price is ₹73.97. The stock opened at ₹72.99, compared to its previous close of ₹72.99. During today's trading session, NOVELIX PHARMACEUTICALS LIMITE share price moved in the range of ₹72.99 to ₹73.99, with an average price of ₹73.49 for the day. Looking at its last 52-week, the stock has touched a low of ₹38.00 and a high of ₹92.00.

₹72.99
1.34% up today
₹73.99
1D LOW
1D HIGH

NOVELIX PHARMACEUTICALS LIMITE Returns Calculator

Circuit
L
H
₹69.35
₹76.63
52-week
L
H
₹38.00
₹92.00

About NOVELIX PHARMACEUTICALS LIMITE

NOVELIX PHARMACEUTICALS LIMITE Share Price
ISIN
INE314I01036
Sector Market Cap
₹ 58.64 Cr

Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.

NOVELIX PHARMACEUTICALS LIMITE Financial Highlights

  • Revenue: NOVELIX PHARMACEUTICALS LIMITE reported revenue of ₹9.16 crore in FY22 vs ₹9.58 crore in FY21. It showed a decrease of 4.38% on a yearly basis.
  • Operating Profit: NOVELIX PHARMACEUTICALS LIMITE reported an operating loss of ₹2.03 crore in FY22 vs ₹3.75 crore in FY21. It showed an increase of 45.87% on a year-on-year basis.
  • Net Profit: NOVELIX PHARMACEUTICALS LIMITE reported a net loss of ₹2.03 crore in FY22 vs ₹3.76 crore in FY21. It showed an increase of 46.01% on a yearly basis.

NOVELIX PHARMACEUTICALS LIMITE Quarterly Result Highlights

  • NOVELIX PHARMACEUTICALS LIMITE reported revenue of ₹1.30 crore in Sep 2022, compared with ₹1.42 crore in Jun 2022, representing a decrease of 8.45% on a quarter-on-quarter (QoQ) basis.
  • NOVELIX PHARMACEUTICALS LIMITE reported an operating loss of ₹0.15 crore in Sep 2022, compared with ₹0.09 crore in Jun 2022, representing a decrease of 66.67% on a quarter-on-quarter (QoQ) basis.
  • NOVELIX PHARMACEUTICALS LIMITE reported a loss of ₹0.15 crore in Sep 2022, compared with ₹0.09 crore in Jun 2022, reflecting a decrease of 66.67% on a QoQ basis.
  • The earnings per share (EPS) of NOVELIX PHARMACEUTICALS LIMITE stood at ₹2.22 during Sep 2022.
Know more
Promoters
54.29%
FII
0.00%
Other DII
0.00%
Retail and other
45.71%
Mutual funds
0.00%
Foreign institutions - FII
FII shareholding by period
Feb 20260.00%
Mar 20260.00%
Jun 20260.00%
Jul 20260.00%
Mkt Cap Cr
58.64
P/E
-27.00
P/B
3.24
ROE
-30.18%
D/E
0.09
ROCE
-32.45%
Div. Yield
0.00%
EPS(TTM)
1.21
Turnover
2.60
EV/EBITDA
-23.57
Net Margin
0.00%
Op. Margin
0.00%
ROA
-30.18%
Quick Ratio
0.00
Curr. Ratio
2.14
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Novelix Pharma. outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Novelix Pharma. appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Novelix Pharma. earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,64,271.0038.325.5613.74%0.6117.33%93.240.83%0.4810.90
Divis Laboratories2,26,843.0077.5513.5315.32%0.0019.56%629.490.35%0.5598.19
Torrent Pharmaceuticals1,86,000.0086.2722.1225.49%1.6913.85%222.760.69%0.4958.70
Zydus Lifesciences1,20,099.0026.154.4318.59%0.3117.35%237.300.08%0.3335.38
Cipla1,18,027.0035.183.4311.27%0.0014.95%423.360.89%0.4543.52
Lupin1,03,549.0018.624.6123.76%0.0424.88%659.050.79%0.57129.18
Mankind Pharma1,00,137.0048.436.1411.74%0.3413.13%397.020.04%0.4449.37
Dr. Reddy's Laboratories1,00,073.0031.442.6311.07%0.1812.54%377.960.67%0.4138.68
Laurus Labs99,474.2091.2318.7716.77%0.4016.14%97.200.11%0.6713.72
Aurobindo Pharma96,700.6026.062.559.25%0.1911.76%391.140.24%0.3841.58

NOVELIX PHARMACEUTICALS LIMITE Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Revenue₹8.61₹9.24₹10.24₹9.89
Other Income₹0.55₹0.34₹0.60₹0.95
Total Revenue₹9.16₹9.59₹10.85₹10.84
Total Expenses₹11.23₹10.35₹11.06₹10.96
Profit Before Tax-₹2.03-₹3.75-₹0.21-₹0.12
Tax-₹0.01₹0.01₹0.04₹0.02
Profit After Tax-₹2.03-₹3.76-₹0.26-₹0.15
EPS - Basic-₹2.22-₹4.62-₹0.35-₹0.30
EPS - Diluted-₹2.22-₹4.62-₹0.35-₹0.30

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Profit before tax-₹2.12-₹3.73-₹0.21-₹0.12
Income before WC changes₹0.01-₹3.80-₹0.41-₹0.16
Change in Assets₹2.21₹5.02₹0.25-₹0.31
Change in Liabilities-₹1.11₹0.39₹0.90-₹0.06
Change in WC₹1.09₹5.42₹1.15-₹0.37
Cash flow from Operations₹1.59₹1.59₹0.63-₹0.53
Cash flow from Investing-₹0.76₹0.14₹0.45₹0.43
Cash flow from Financing₹0.00-₹0.77-₹0.16-₹0.05
Total Cash Flow₹0.83₹0.96₹0.92-₹0.15
Cash (Start of the year)₹2.06₹1.12₹0.20₹0.35
Cash (End of the year)₹2.89₹2.08₹1.12₹0.20

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Non-Current Assets₹2.81₹2.24₹2.33₹2.62
Current Assets₹5.93₹7.33₹11.39₹10.72
Total Assets₹8.74₹9.57₹13.72₹13.34
Current Liabilities₹0.93₹2.18₹1.81₹0.99
Net Current Asset₹5.00₹5.16₹9.58₹9.73
Non-Current Liabilities₹0.13₹0.03₹0.79₹0.93
Equity Capital₹7.68₹7.37₹11.13₹11.42
Total Equity & Liabilities₹8.74₹9.57₹13.72₹13.34

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹30.72₹4.22₹1.40₹0.84
Other Income₹0.02₹0.31₹0.52₹0.55
Total Revenue₹30.73₹4.53₹1.92₹1.39
Total Expenses₹30.61₹4.51₹1.98₹2.96
Profit Before Tax₹0.12₹0.02-₹0.06-₹1.57
Tax₹0.04₹0.01₹0.00-₹0.01
Profit After Tax₹0.08₹0.01-₹0.06-₹1.56
EPS - Basic₹0.09₹0.01-₹0.07-₹1.93
EPS - Diluted₹0.09₹0.01-₹0.07-₹1.93

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Profit before tax₹0.12₹0.02-₹0.06-₹1.57
Income before WC changes₹0.15-₹0.25-₹0.52-₹0.53
Change in Assets-₹22.24-₹0.04-₹1.94₹1.14
Change in Liabilities₹8.41-₹0.05₹0.05-₹0.02
Change in WC-₹13.83-₹0.10-₹1.89₹1.12
Cash flow from Operations-₹13.68-₹0.34-₹2.41₹0.59
Cash flow from Investing₹2.93₹0.19₹0.08₹0.28
Cash flow from Financing₹11.32₹0.00₹0.00₹0.00
Total Cash Flow₹0.56-₹0.16-₹2.33₹0.87
Cash (Start of the year)₹0.12₹0.27₹2.60₹1.74
Cash (End of the year)₹0.68₹0.12₹0.27₹2.60

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹0.27₹3.24₹3.01₹2.62
Current Assets₹26.93₹4.13₹4.24₹4.63
Total Assets₹27.21₹7.36₹7.26₹7.25
Current Liabilities₹9.67₹0.01₹0.06₹0.01
Net Current Asset₹17.27₹4.12₹4.18₹4.62
Non-Current Liabilities₹0.00₹0.00₹0.00₹0.00
Equity Capital₹17.54₹7.35₹7.20₹7.24
Total Equity & Liabilities₹27.21₹7.36₹7.26₹7.25
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
73.96
10
73.97
139
0
0
0
0
0
0
Bid Total: 0
Ask Total: 149
Buy orders: 0%
Sell orders: 100%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
52.82
Neutral
ATR (14)
4.4
Neutral
STOCH(9,6)
50.04
Neutral
STOCH RSI (14)
54.12
Neutral
ADX(9)
19.83
Bullish
UO(9)
50.59
Neutral
ROC(12)
-0.56
Bearish
WillR(14)
-47.96
Neutral
Period
Simple value
Exponential vaue
5D
73.52
73.31
10D
71.51
72.29
20D
70.36
71.54
50D
72.95
69.78
100D
63.87
66.73
Volume trend — traded volume by day
13 Aug0L
12 Aug0L
11 Aug0L
10 Aug0L
7 Aug0L
Average0L
Compare against other stocks
NOVELIX PHARMACEUTICALS LIMITE Share Price
NOVELIX PHARMACEUTICALS LIMITE
Trading
Add Stock
Add Another

NOVELIX PHARMACEUTICALS LIMITE Share Price FAQs